JP2021530501A5 - - Google Patents
Info
- Publication number
- JP2021530501A5 JP2021530501A5 JP2021500920A JP2021500920A JP2021530501A5 JP 2021530501 A5 JP2021530501 A5 JP 2021530501A5 JP 2021500920 A JP2021500920 A JP 2021500920A JP 2021500920 A JP2021500920 A JP 2021500920A JP 2021530501 A5 JP2021530501 A5 JP 2021530501A5
- Authority
- JP
- Japan
- Prior art keywords
- apmv
- nucleotide sequence
- sequence encoding
- pharmaceutical composition
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697944P | 2018-07-13 | 2018-07-13 | |
| US62/697,944 | 2018-07-13 | ||
| PCT/US2019/041568 WO2020014591A1 (en) | 2018-07-13 | 2019-07-12 | Apmv and uses thereof for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530501A JP2021530501A (ja) | 2021-11-11 |
| JP2021530501A5 true JP2021530501A5 (enExample) | 2022-07-26 |
Family
ID=69141914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500920A Pending JP2021530501A (ja) | 2018-07-13 | 2019-07-12 | 癌の治療のためのａｐｍｖ及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200297787A1 (enExample) |
| EP (1) | EP3820492A4 (enExample) |
| JP (1) | JP2021530501A (enExample) |
| CN (1) | CN112739359A (enExample) |
| CA (1) | CA3106170A1 (enExample) |
| WO (1) | WO2020014591A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| EP4110803A4 (en) * | 2020-02-27 | 2024-03-27 | Icahn School of Medicine at Mount Sinai | VEGFR-3 ACTIVATING AGENTS AND ONCOLYTIC VIRUSES AND THEIR USES FOR THE TREATMENT OF CANCER |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| US20230372472A1 (en) * | 2020-09-25 | 2023-11-23 | President And Fellows Of Harvard College | Immunotherapeutic virus for the treatment of cancer |
| AU2022267223A1 (en) * | 2021-04-26 | 2023-11-02 | Icahn School Of Medicine At Mount Sinai | Chimeric newcastle disease virus expressing apmv hn and f proteins |
| CN117925916A (zh) * | 2024-03-11 | 2024-04-26 | 广州市金域转化医学研究院有限公司 | Hpv dna的e6基因在制备浸润性宫颈癌诊断产品中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0974660A1 (en) * | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| JP2008519590A (ja) * | 2004-11-12 | 2008-06-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 組換えニューカッスル病ウィルス |
| US20090208495A1 (en) * | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| PL2467158T3 (pl) * | 2009-08-21 | 2017-07-31 | Merial, Inc. | Rekombinowana szczepionka z paramyksowirusem ptaków oraz sposób jej wytwarzania i zastosowania |
| ES2492691T3 (es) * | 2010-06-10 | 2014-09-10 | Intervet International B.V. | Composición antitumoral |
| EP2968525A4 (en) * | 2013-03-14 | 2016-10-26 | Icahn School Med Mount Sinai | MORBUS NEWCASTLE VIRUSES AND USES THEREOF |
| HUE042382T2 (hu) * | 2013-09-03 | 2019-06-28 | Medimmune Ltd | Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra |
-
2019
- 2019-07-12 CN CN201980060371.XA patent/CN112739359A/zh active Pending
- 2019-07-12 WO PCT/US2019/041568 patent/WO2020014591A1/en not_active Ceased
- 2019-07-12 CA CA3106170A patent/CA3106170A1/en active Pending
- 2019-07-12 JP JP2021500920A patent/JP2021530501A/ja active Pending
- 2019-07-12 EP EP19834094.5A patent/EP3820492A4/en active Pending
- 2019-07-12 US US16/645,378 patent/US20200297787A1/en not_active Abandoned
-
2021
- 2021-11-16 US US17/527,903 patent/US20220241358A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530501A5 (enExample) | ||
| US20240058383A1 (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
| Chaurasiya et al. | Oncolytic viruses and immunity | |
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| JP2016513115A5 (enExample) | ||
| CN108841796A (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
| JP7239910B2 (ja) | 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用 | |
| Williams et al. | Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector | |
| WO2017195032A1 (en) | Combination prime: boost therapy | |
| Malfitano et al. | Virotherapy as a potential therapeutic approach for the treatment of aggressive thyroid cancer | |
| CN105177045A (zh) | 表达人白介素15的重组溶瘤腺病毒及其构建方法 | |
| Jindra et al. | Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients | |
| Ip et al. | Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines | |
| Sokke Umeshappa et al. | CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination | |
| Jiang et al. | Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors | |
| JP2021522190A (ja) | 腫瘍を治療するためのコクサッキーウイルスｂ群 | |
| Hatami et al. | Interleukin-12 encoded by the oncolytic virus VSV-GP enhances therapeutic antitumor efficacy by inducing CD8+ T-cell responses with a long-lived effector cell phenotype | |
| CN119736337A (zh) | Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗 | |
| Hou et al. | A novel chimpanzee adenovirus vector vaccine for protection against infectious bronchitis and Newcastle disease in chickens | |
| Letafati et al. | Oncolytic viruses against cancer, promising or delusion? | |
| TWI259206B (en) | A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof | |
| JP2013529082A (ja) | 遺伝子組み換えｒｓウイルスを使用した乳がん治療 | |
| WO2025222396A1 (en) | Oncolytic viral therapy for treating and preventing human papillomavirus (hpv) -associated malignancies | |
| HK40097194A (en) | Adoptive cell transfer and oncolytic virus combination therapy | |
| Buchatskyi et al. | Vesiculoviruses as a tool of biotechnology |